The National Biome Initiative: An allergy perspective - 19/04/17

Doi : 10.1016/j.jaci.2017.02.008

Glenn T. Furuta, MD ^a, Seema S. Aceves, MD, PhD ^b,^⁎
^a Division of Gastroenterology, Children's Hospital of Colorado, Aurora
^b Division of Allergy and Immunology, Center for Infection, Immunity, and Inflammation, Departments of Pediatrics and Medicine, Rady Children's Hospital, University of California, San Diego

^∗Corresponding author: Seema S. Aceves, MD, PhD, Division of Allergy and Immunology, Center for Immunity, Infection, and Inflammation, 9500 Gilman Dr, MC-0760, La Jolla, CA 92093-0760.Division of Allergy and ImmunologyCenter for Immunity, Infection, and Inflammation9500 Gilman Dr, MC-0760La JollaCA92093-0760

El texto completo de este artículo está disponible en PDF.

Key words : Eosinophilic esophagitis, microbiome, asthma, allergy, biome initiative

El texto completo de este artículo está disponible en PDF.

Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grant AI 092135 and Office of Rare Disease Research (ORDR)/National Center for Advancing Translational Sciences (NCATS)/NIAID/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) CEGIR grant U54 AI117804 (G.T.F. and S.S.A.). CEGIR (U54 AI117804) is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS, and is funded through collaboration between NIAID, NIDDK, and NCATS. CEGIR is also supported by patient advocacy groups including APFED CURED and EFC.

Disclosure of potential conflict of interest: G. T. Furuta has consultant arrangements with Shire, has received a grant from the National Institutes of Health, and has received royalties from UpToDate. S. S. Aceves has received a grant and travel support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, is a member of the Medical Advisory Board for the American Partnership for Eosinophilic Disorders, has a patent for oral viscous budesonide.